IMMOBILIZED PROTEINS WITH SPECIFIC BINDING CAPACITIES AND THEIR USE IN PROCESSES AND PRODUCTS

Abstract: A method is provided for immobilizing a binding protein capable of binding to a specific compound, using recombinant DNA techniques for producing said binding protein or a functional part thereof. The binding protein is immobilized by producing it as part of a chimeric protein also comprising an anchoring part derivable from the C-terminal part of an anchoring protein, thereby ensuring that the binding protein is localized in or at the exterior of the cell wall of the host cell. Suitable anchoring proteins are yeast alpha -agglutinin, FLO1 (a protein associated with the flocculation phenotype in S. cerevisiae), the Major Cell Wall Protein of lower eukaryotes, and a proteinase of lactic acid bacteria. For secretion the chimeric protein can comprise a signal peptide including those of alpha -mating factor of yeast, alpha -agglutinin of yeast, invertase of Saccharomyces, inulinase of Kluyveromyces, alpha -amylase of Bacillus, and proteinase of lactic acid bacteria. Also provided are recombinant polynucleotides encoding such chimeric protein, vectors comprising such polynucleotide, transformed microorganisms having such chimeric protein immobilized on their cell wall, and a process for carrying out an isolation process by using such transformed host, wherein a medium containing said specific compound is contacted with such host cell to form a complex, separating said complex from the medium and, optionally, releasing said specific compound from said binding protein.

Description: Title: Immobilized proteins with specific binding capacities and their use in processes and products Background of the invention The pharmaceutical, the fine chemicals and the food industry need a number of compounds that have to be isolated from complex mixtures such as extracts of animal or plant tissue, or fermentation broth. Often these isolation processes determine the price of the product. Conventional isolation processes are not very specific and during the isolation processes the compound to be isolated is diluted considerably with the consequence that expensive steps for removing water or other solvents have to be applied. For the isolation of some specific compounds affinity techniques are used. The advantage of these techniques is that the compounds bind very specifically to a certain ligand. However these ligands are quite often very expensive. To avoid spillage of these expensive ligands they can be linked to an insoluble support. However, often linking the ligand is also expensive and, moreover, the functionality of the ligand is often affected negatively by such procedure. So a need exists for developing cheap processes for preparing highly effective immobilized ligands. Summary of the invention The invention provides a method for immobilizing a binding protein capable of binding to a specific compound, comprising the use of recombinant DNA techniques for producing said binding protein or a functional part thereof still having said specific binding capability, said protein or said part thereof being linked to the outside of a host cell, whereby said binding protein or said part thereof is localized in the cell wall or at the exterior of the cell wall by allowing the host cell to produce and secrete a chimeric protein in which said binding protein or said functional part thereof is bound with its C-terminus to the N-terminus of an anchoring part of an anchoring protein capable of anchoring in the cell wall of the host cell, which anchoring part is derivable from the C-terminal part of said anchoring protein. Preferably, the host is selected from Gram-positive bacteria and fungi, which have a cell wall at the outside of the host cell, in contrast to Gram-negative bacteria and cells of higher eukaryotes such as animal cells and plant cells, which have a membrane at the outside of their cells. Suitable Gram-positive bacteria comprise lactic acid bacteria and bacteria belonging to the genera Bacillus and Streptomyces. Suitable fungi comprise yeasts belonging to the genera Candida, Debaryomyces, Han- senula, Kluyveromyces, Pichia and Sacc aro yces, and moulds belonging to the genera Λspergillus, Pemcillium and Rhizopus. In this specification the group of fungi comprises the group of yeasts and the group of moulds, which are also known as lower eukaryotes. In contrast to the cells in plants and animals, the group of bacteria and lower eukaryotes are also indicated in this specification as microorganisms. The invention also provides a recombinant polynucleotide capable of being used in a method as described above, such polynucleotide comprising (i) a structural gene encoding a binding protein or a functional part thereof still having the specific binding capability, and (ii) at least part of a gene encoding an anchoring protein capable of anchoring in the cell wall of a Gram-positive bacterium or a fungus, said part of a gene encoding at least the anchoring part of said anchoring protein, which anchoring part is derivable from the C-terminal part of said anchoring protein. The anchoring protein can be selected from α-agglutinin, a-agglutinin, FLOl, the Major Cell Wall Protein of a lower eukaryote, and proteinase of lactic acid bacteria. Preferably, such polynucleotide further comprises a nucleotide sequence encoding a signal peptide ensuring secretion of the expression product of the polynucleotide, which signal peptide can be derived from a protein selected from the α-mating factor of yeast, α-agglutinin of yeast, invertase of Saccharomyces, inulinase of -Kluyveromyces, α-amylase of Bacillus, and proteinase of lactic acid bacteria. The polynucleotide can be operably linked to a promoter, which is preferably an inducible promoter. The invention further provides a recombinant vector comprising a polynucleotide according to the invention, a chimeric protein encoded by a polynucleotide according to the invention, and a host cell having a cell wall at the outside of its cell and containing at least one polynucleotide according to the invention. Preferably at least one polynucleotide is integrated in the chromosome of the host cell. Another embodiment of this part of the invention is a host cell having a chimeric protein according to the invention immobilized in its cell wall and having the binding protein part of the chimeric protein localized in the cell wall or at the exterior of the cell wall. Another embodiment of the invention is a process for carrying out an isolation process by using an immobilized binding protein or functional part thereof still capable of binding to a specific compound, wherein a medium containing said specific compound is contacted with a host cell according to the invention under conditions whereby a complex between said specific compound and said immobilized binding protein is formed, separating said complex from the medium originally containing said specific compound and, optionally, releasing said specific compound from said binding protein or functional part thereof. Brief description of the figures In Figure 1 the composition of pEMBL9-derived plasmid pUR4122 is indicated, the preparation of which is described in Example 1. In Figure 2 the composition of plasmid pUR2741 is indicated, which is a derivative of published plasmid pUR2740, see Example 1. In Figure 3 the composition of pEMBL9-derived plasmid pUR2968 is indicated. Its preparation is described in Example 1. In Figure 4 the preparation of plasmid pUR4174 starting from plasmids pUR2741, pUR2968 and pUR4122 is indicated, as well as the preparation of plasmid pUR4175 starting from plasmids pSYlό, pUR2968 and pUR4122. These preparations are described in Example 1. In Figure 5 the composition of plasmid pUR2743.4 is indicated. Its preparation is described in Example 2. It contains the 714 bp Pstl-Xhόl fragment given in SEQ ID NO: 12, which fragment encodes an scFv-TRAS fragment of anti-traseolide ® antibody 02/01/01. In Figure 6 the composition of plasmid pUR4178 is indicated. Its preparation is indicated in Example 2. It contains the above mentioned 714 bp Pstl-Xhol fragment given in SEQ ID NO: 12. This plasmid is suitable for the expression of a fusion protein between scFv-TRAS and αAGG preceded by the invertase signal sequence (SUC2). In Figure 7 the composition of plasmid pUR4179 is indicated. Its preparation is indicated in Example 2. It contains the above mentioned 714 bp Pstl-Xhol fragment given in SEQ ID NO: 12. This plasmid is suitable for the expression of a fusion protein between scFv-TRAS and αAGG preceded by the prepro-α-mating factor signal signal sequence. In Figure 8 a molecular design picture is given, showing the musk odour molecule traseolide ® and a modified musk antigen, described in Example 3. In Figure 9 the composition of plasmid pUR4177 is indicated. Its construction is described in Example 4. Plasmid pUR4177 contains the 734 bp Eagl-Xhol DNA fragment given in SEQ ID NO: 13 encoding the variable regions of the heavy and light chain fragments from the monoclonal antibody directed against the human chorionic gonadotropin (an scFv-HCG fragment) and is a 2 μm-based vector suitable for production of the chimeric scFv HCG-αAGG fusion protein preceded by the invertase signal sequence and under the control of the GAL7 promoter. In Figure 10 the composition of plasmid pUR4180 is indicated. Its preparation is indicated in Example 4. It contains the above mentioned 734 bp Eagl-Xhol DNA fragment given in SEQ ID NO: 13 and is a 2 μm-based vector suitable for production of the chimeric scFv-HCG-αAGG fusion protein preceded by the prepro- α-mating factor signal sequence and under the control of the GAL7 promoter. In Figure 11 the composition of plasmid pUR2990, a 2 μm-based vector, is indicated, which is suggested in Example 5 as a starting vector for the preparation of plasmid pUR4196 (see Figure 12). Plasmid pUR2990 contains a DNA fragment encoding a chimeric lipase-FLOl protein that will be anchored in the cell wall of a lower eukaryote and can catalyze lipid hydrolysis. In Figure 12 the composition of plasmid pUR4196 is indicated. Its preparation is explained in Example 5. It contains a DNA fragment encoding a chimeric protein comprising the scFv-HCG followed by the C-terminal part of the FLOl-protein, and is a vector suitable for the production of a chimeric protein anchored in the cell wall of the host organism and can bind HCG. In Figure 13 the composition of plasmid pUR2985 is indicated. Its preparation is described in Example 6. It contains a c oB gene coding for the mature part of the cholesterol oxidase (EC 1.1.3.6) obtained via PCR techniques from the chromosome of Brevibacterium sterolicum. In Figure 14 the composition of plasmid pUR2987 is indicated. Its preparation from plasmid pUR2985 is described in Example 6. It contains a DNA sequence comprising the c/ioB gene coding for the mature part of the cholesterol oxidase preceded by DNA encoding the prepro-α-mating factor signal sequence and followed by DNA encoding the C-terminal part of α-agglutinin. In Figure 15 the composition of the published plasmid pGKV550 is indicated. It is described in Example 7 and contains the complete cell wall proteinase operon of Lactococcus lactis subsp. cremoris Wg2, including the promoter, the ribosome binding site and the prtP gene. In Figure 16 the composition of plasmid pUR2988 is indicated. Its preparation is described in Example 7. It is anticipated that this plasmid can be used for preparing a further plasmid pUR2989, which after introduction in a lactic acid bacterium will be responsible for producing a chimeric protein that will be anchored at the outer surface of the lactic acid bacterium and is capable of binding cholesterol. In Figure 17 the composition of plasmid pUR2993 is indicated. Its preparation is described in Example 8. It is anticipated that this plasmid can be used for transforming yeast cells that can bind a human epidermal growth factor (EGF) through an anchored chimeric protein containing an EGF receptor. In Figure 18 the composition of plasmids pUR4482 and 4483 is indicated. Their preparation is described in Example 9. Plasmid pUR4482 is a yeast episomal expression plasmid for expression of a fusion protein with the invertase signal sequence, the CH V 09 variable region, the Myc-tail, and the "X-P-X-P" Hinge region of a camel antibody, and the α-agglutinin cell wall anchor region. Plasmid pUR4483 differs from pUR4482 in that it does not contain the "X-P-X-P" Hinge region. In Figure 19 immunofluorescent labelling (anti-Myc antibody) of SU10 cells in the exponential phase (OD 530 = 0.5) expressing the genes of camel antibodies present on plasmids pUR4424, pUR4482 and pUR4483 is shown. Ph = phase contrast, FI = fluorescence. In Figure 20 immunofluorescent labelling (anti-human IgG antibody) of SU10 cells in the exponential phase (OD 530 = 0.5) expressing the genes of camel antibodies present on plasmids pUR4424, pUR4482 and pUR4483 is shown. Ph = phase contrast, FI = fluorescence. Abbreviations used in the Figures: α-gal: gene encoding guar α-galactosidase AG-alpha-1/AGαl: gene expressing α-agglutinin from S. cerevisiae AGαl cds/α-AGG: coding sequence of α-agglutinin Amp/amp r: β-lactamase resistance gene CHv09: camel heavy chain variable 09 fragment EmR: erythromycin resistance gene fl: phage f 1 replication sequence FLOl/FLO (C-part): C-terminal part of FLOl coding sequence of flocculation protein Hinge: Camel "X-P-X-P" Hinge region, see Example 9 LEU2: LEU2 gene LEU2d/Leu2d: truncated LEU2 gene Leu 2d cs: coding sequence LEU2d gene MycT: camel Myc-tail Ori MB1: origin of replication MB1 derived from E. coli plasmid Pgal7/pGAL7: GAL7 promoter Tpgk: terminator of the phosphoglyceratekinase gene ppα-MF/MFα lss prepro-part of α-mating factor (= signal sequence) repA: gene encoding the repA protein required for replication (Fig. 15/16). ScFv (Vh-Vl) single chain antibody fragment containing V H and V L chains ss: signal sequence SUC2: invertase signal sequence 2u/2 micron: 2μm sequence Detailed description of the invention The present invention relates to the isolation of valuable compounds from complex mixtures by making use of immobilized ligands. The immobilized ligands can be proteins obtainable via genetic engineering and can consist of two parts, namely both an anchoring protein or functional part thereof and a binding protein or functional part thereof. The anchoring protein sticks into cell walls of microorganisms, preferably lower eukaryotes, e.g. yeasts and moulds. Often this type of proteins has a long C-terminal part that anchors it in the cell wall. These C-terminal parts have very special amino acid sequences. A typical example is anchoring via C-terminal sequences of proteins enriched in proline, see Kok (1990). The C-terminal part of these anchoring proteins can contain a substantial number of potential serine and threonine glycosylation sites. O-glycosylation of these sites gives a rod-like conformation to the C-terminal part of these proteins. In the case of anchored manno-proteins they seem to be linked to the glucan in the cell wall of lower eukaryotes, as they cannot be extracted from the cell wall with sodium dodecyl sulphate (SDS), but can be liberated by glucanase treatment, see our co-pending patent application O-94/01567 (UNILEVER) published 20 January 1994 and Schreuder cs. (1993), both being published after the claimed priority date. Another mechanism to anchor proteins at the outer side of a cell is to make use of the property that a protein containing a glycosyl-phosphatidyl-inositol (GPI) group anchors via this GPI group to the cell surface, see Conzelmann c.s. (1990). The binding protein is so called, because it ligates or binds to the specific compound to be isolated. If the N-terminal part of the anchoring protein is sufficiently capable of binding to a specific compound, the anchoring protein itself can be used in a . process for isolating that specific compound. Suitable examples of a binding protein comprise an antibody, an antibody fragment, a combination of antibody fragments, a receptor protein, an inactivated enzyme still capable of binding the corresponding substrate, and a peptide obtained via Applied Molecular Evolution, see Lewin (1990), as well as a part of any of these proteinaceous substances still capable of binding to the specific compound to be isolated. All these binding proteins are characterized by specific recognition of the compounds or group of related compounds to be isolated. The binding rate and release rate, and therefore the binding constant between the specific compound to be isolated and the binding protein, can be regulated either by changing the composition of the liquid extract in which the compound is present or, preferably, by changing the binding protein by protein engineering. The gene coding for the chimeric protein comprising both the binding protein and the anchoring protein (or functional parts thereof) can be placed under control of a constitutive, inducible or derepressible promoter and will generally be preceded by a DNA fragment encoding a signal sequence ensuring efficient secretion of the chimeric protein. Upon secretion the chimeric protein will be anchored in the cell wall of the microorganisms, thereby covering the surface of the microorganisms with the chimeric protein. These microorganisms can be obtained in normal fermentation processes and their isolation is a cheap process, when physical separation processes are used, e.g. centrifugation or membrane filtration. After washing, the isolated microorganisms can be added to liquid extracts containing the valuable specific compound or compounds. After some time the equilibrium between the bound and free specific compound(s) will be reached and the microorganisms to which the specific compound or group of related compounds is bound can be separated from the extract by simple physical techniques. Alternatively, the microorganisms covered with ligands can be brought on a support material and subsequently this coated support material can be used in a column. The liquid extract containing the specific compound or compounds of interest can be added to the column and afterwards the compound(s) can be released from the ligand by changing the composition of the eluting liquid or the temperature or both. A skilled person will recognize that in addition to these two possibilities other modifications can be used for effecting the binding of the specific compound and the ligand, their subsequent isolation and/or the release of the specific compound(s). In particular the invention relates lo chimeric proteins that are bound to the cell wall of lower eukaryotes. Suitable lower eukaryotes comprise yeasts, e.g. Candida, Debaiyomyces, Hansenuki, Kluyveromyces, Pichia and Saccharomyces, and moulds e.g. Aspergillus, Penicillium and Rhizopus. For some applications prokaryotes are also applicable, especially Gram-positive bacteria, examples of which include lactic acid bacteria, and bacteria belonging to the genera Bacillus and Streptomyces. For lower eukaryotes the present invention provides genes encoding chimeric proteins consisting of: a. a DNA sequence encoding a signal sequence functional in a lower eukaryotic host, e.g. derived from a yeast protein including the α-mating factor,invertase, α-agglutinin, inulinase or derived from a mould protein e.g. xylanase; b. a structural gene encoding a C-terminal part of a cell wall protein preceded by a structural gene encoding a protein, that is capable of binding to the specific compound or group of compounds of interest, examples of which include - an antibody, - a single chain antibody fragment (scFv; see Bird and Webb Walker (1991), - a variable region of the heavy chain (V H ) or a variable region of the light chain (V L ) of an antibody or that part of such variable region still containing one to three of the complementarity determining regions (CDRs), - an agonist-recognizing part of a receptor protein or a part thereof still capable of binding the agonist, - a catalytically inactivated enzyme, or a fragment of such enzyme still containing a substrate binding site of the enzyme, - specific lipid binding proteins or parts of these proteins still containing the lipid binding site(s), see Ossendorp (1992), and - a peptide that has been obtained via Applied Molecular Evolution, see Lewin (1990). All expression products of these genes are characterized in that they consists of .a signal sequence and both a protein part, that is capable of binding to the compound(s) to be isolated, and a C-terminus of a typically cell wall bound protein, examples of the latter including α-agglutinin, see Lipke c.s. (1989), a-agglutinin, see Roy cs. (1991), FLOl (see Example 5 and SEQ ID NO: 14) and the Major Cell Wall Protein of lower eukaryotes, which C-terminus is capable of anchoring the expression product in the cell wall of the lower eukaryote host organism. The expression of these genes encoding chimeric proteins can be under control of a constitutive promoter, but an inducible promoter is preferred, suitable examples of which include the GAL7 promoter from Saccharomyces, the inulinase promoter from Kluyveromyces, the methanol-oxidase promoter from Hansenula, and the xylanase promoter of Aspergillus. Preferably the constructs are made in such a way that the new genetic information is integrated in a stable way in the chromosome of the host cell, see e.g. WO-91/00920 (UNILEVER). The lower eukaryotes transformed with the above mentioned genes can be grown in normal fermentation, continous fermentation, or fed batch fermentation processes. The selection of a suitable process for growing the microorganism will depend on the construction of the gene and the promoter used, and on the desired purity of the cells after the physical separation procedure(s). For bacteria the present invention deals with genes encoding chimeric proteins consisting of: a. a DNA sequence encoding a signal sequence functional in the specific bacterium, e.g. derived from a Bacillus α-amylase, a Bacillus subtilis subtilisin, or a Lactococcus lactis subsp. cremoris proteinase; b. a structural gene encoding a C-terminal part of a cell wall protein preceded by a structural gene encoding a protein capable of binding to the specific compound or group of compounds of interest, examples of which are given above for a lower eukaryote. All expression products of these genes are characterized in that they consist of a signal sequence and both a protein part, that is capable of binding to the specific compound or specific group of compounds to be isolated, and a C-terminus of a typically cell wall-bound protein such as the proteinase of Lactococcus lactis subsp. cremoris strain Wg2, see Kok c.s. (1988) and Kok (1990), the C-terminus of which is capable of anchoring the expression product in the cell wall of the host bacterium. The invention is illustrated with the following Examples without being limited thereto. First the endonuclease restriction sites mentioned in the Examples are given. BstEII G GTNACC Clal AT CGAT Eagl C GGCCG CCANTG G TAGC TA GCCGG C EcoRl G AATTC Hindlll A AGCTT Nhel G CTAGC CTTAA G TTCGA A CGATC G Not! GC GGCCGC Wrul TCG CGA Pstl CTGCA G CGCCGG CG AGC GCT G ACGTC Sacl GAGCT C Sail G TCGAC Xhol C TCGAG C TCGAG CAGCT G GAGCT C Example 1. Construction of a gene encoding a chimeric protein that will be anchored in the cell wall of a lower eukaryote and is able to bind with high specificity lysozyme from a complex mixture. Lysozyme is an anti-microbial enzyme with a number of applications in the pharmaceutical and food industries. Several sources of lysozyme are known, e.g. egg yolk or a fermentation broth containing a microorganism producing lysozyme. Monoclonal antibodies have been raised against lysozyme, see Ward cs. (1989), and the mRNAs encoding the light and heavy chains of such antibodies have been isolated from the hybridoma cells and used as template for the synthesis of cDNA using reverse transcriptase. Starting from the plasmids as described by Ward cs. (1989), we constructed a pEMBL-derived plasmid, designated pUR4122, in which the multiple cloning site of the pEMBL-vector, ranging from the EcoRl to the H dlll site, was replaced by a 231 bp DNA fragment, whose nucleotide sequence is given in SEQ ID NO: 1 and has an EcoRl site (GAATTC) at nucleotides 1-6, a Pstl site (CTGCAG) at nucleotides 105-1 0, a BstEII site (GGTCACC) at nucleotides 122-128, a Xhol site (CTCGAG) at nucleotides 207-212, and a H dIII site (AAGCTT) at nucleotides 226-231. Construction of pU 4122 Plasmid pEMBL9, see Denie c.s. (1983), was digested with EcoRl and Hindlll and the resulting large fragment was ligated with the double stranded synthetic DNA fragment given in SEQ ID NO: 1. For the successive ligation of DNA fragments, which finally form the coding sequence of a single chain antibody fragment for lysozyme, the following elements were combined in the 231 bp DNA fragment (SEQ ID NO: 1) inserted into the pEMBL-9 vector: the 3' part of the GAL7 promoter, the invertase signal sequence (SUC2), a Pstl restriction site, a BstEII restriction site, a sequence encoding the (GGGGS)x3 peptide linker connecting the V H and V L frag- ments, a Sac\ restriction site, a Xhol restriction site and a H/ ' «dIII restriction site, resulting in plasmid pUR4119. To obtain the in frame fusion between V H and the GGGGS-linker plasmid pSWl-VHD1.3-VKD1.3-TAGl, see Ward cs. (1989), was digested with Pstl and BstEII and a DNA fragment of 0.35 kbp was ligated in the correspondingly digested pUR4119 resulting in plasmid pUR4119A Subsequently the plasmid pSWl-VHD1.3-VKD1.3-TAGl was digested with Sαcl and Xfiol and this fragment containing the coding part of V L was finally ligated into the Sacl/Xhol sites of pUR4119A, resulting in plasmid pUR4122 (see Figure 1). Construction of pUR4174. see Figure 4 To obtain S. ccrevisiae episomal expression plasmids containing DNA encoding a cell wall anchor derived from the C-terminal part of α-agglutinin, plasmid pUR2741 (see Figure 2) was selected as starting vector. Basically, this plasmid is a derivative of pUR2740, which is a derivative of plasmid pUR2730 as described in WO-91/19782 (UNILEVER) and by Verbakel (1991). The preparation of pUR2730 is clearly described in Example 9 of EP-Al-0255153 (UNILEVER). Plasmid pUR2741 differs from plasmid pUR2740 in that the Eagl restriction site within the remaining part of the already inactive tel resistance gene was deleted through Nrul/Sall digestion. The Sail site was filled in prior to religation. After digesting pUR4 22 with Sad (partially) and Hinάlll, the approximately 800 bp fragment was isolated and cloned into the pUR2741 vector fragment, which was obtained after digestion of pUR2741 with the same enzymes. The resulting plasmid was named pUR4125. A plasmid named pUR2968 (see Figure 3) was made by (1) digesting with H dIII the Agal -containing plasmid pLα2l published by Lipke c.s. (1989), (2) isolating an about 6.1 kbp fragment and (3) ligating that fragment with HmdIII-treated pEMBL9, so that the 6.1 kbp fragment was introduced into the HmdIII site present in the multiple cloning site of the pEMBL9 vector. Plasmid pUR4125 was digested with Xhol and HmdIII and the about 8 kbp fragment was ligated with the approximately 1.4 kbp Nhe -Hinύlll fragment of pUR2968, using Xhol/Nhel adapters having the following sequence: Xhol Nhel 5'-TC GAG ATC AAA GGC GGA TCT G -3' = SEQ ID NO: 2 3'- C TAG TTT CCG CCT AGA CGATC-5 ■ = SEQ ID NO: 3. The plasmid resulting from the ligation of the appropriate parts of plasmids pUR2968, pUR4125 and Xhol/Nhel adapters, was designated pUR4174 and encodes a chimeric fusion protein at the amino terminus consisting of the invertase signal (pre) peptide, followed by the scFv-LYS polypeptide and, finally, the C-terminal part of α-agglutinin (see Figure 4). Construction of pUR4175. see Figure 4 Upon digesting pUR4122 (see above) with Pstl and HmdIII, the approximately 700 bp fragment was isolated and ligated into a vector fragment of plasmid pSY16, see Ηarmsen c.s. (1993), which was digested with Eagl and HmdIII and using Eagl-Pstl adapters, having the following sequence: Eagl Pstl 5•-G GCC GCC CAG GTG CAG CTG CA-3• = SEQ ID NO: 4 3'- CGG GTC CAC GTC G -5 » = SEQ ID NO: 5 The resulting plasmid, named pUR4132, was digested with Xhol and HmdIII and ligated with the approximately 1.4 kbp Nhel-Hinύlll fragment of pUR2968 (see above), using Xhol/Nhel adapters as described above, resulting in pUR4175 (see Figure 4). This plasmid contains a gene encoding a chimeric protein consisting of the α-mating factor prepro-peptide, followed by the scFv-LYS polypeptide and, finally, the C-terminal part of α-agglutinin. Example 2. Construction of genes encoding a series of homologous chimeric proteins that will be anchored in the cell wall of a lower eukaryote and are able to bind with high specificities the musk fragrance traseolide® from a complex mixture. The isolation of RNA from the hybridoma cell lines, the preparation of cDNA and amplification of gene fragments encoding the variable regions of antibodies by PCR was performed according to standard procedures known from the literature, see e.g. Orlandi cs. (1989). For the PCR amplification different oligonucleotide primers have been used. For the heavy chain fragment: A: AGG TSM ARC TGC AGS AGT CWG G = SEQ ID NO: 6 Pstl in which S is C or G, M is A or C, R is A or G, and W is A or T, and B: TGA GGA GAC GGT GAC CGT GGT CCC TTG GCC CC BstEII = SEQ ID NO: 7. For the light chain fragment (Kappa): C: GAC ATT GAG CTC ACC CAG TCT CCA = SEQ ID NO: 8, Sod and D: GTT TGA TCT CGA GCT TGG TCC C = SEQ ID NO: 9. Xhol Construction of pUR4143 To simplify future construction work an Eagl restriction site was introduced in pUR4122 (see above), at the junction between the invertase signal sequence and the scFv-LYS. This was achieved by replacing the about 110 bp EcoRI-jRytl fragment within the synthetic fragment given in SEQ ID NO: 1 by synthetic adapters with the following sequence: EcoRl Pstl AATTCGGCCGTTCAGGTGCAGCTGCA = SEQ ID NO: 10 GCCGGCAAGTCCACGTCG = SEQ ID NO: 11. The resulting plasmid was designated pUR4122.1: a construction vector for single chain Fv assembly in frame behind an Eagl site for expression behind either the prepro-α-mating factor sequence or the SUC2 invertase signal sequence. After digesting the heavy chain PCR fragment with Pstl and BstEII, two fragments were obtained: a Pstl fragment of about 230 bp and a Pstl /BstEII fragment of about 110 bp. The latter fragment was cloned into vector pUR4122.1, which was digested with Pstl and BstEII. The newly obtained plasmid (pUR4122.2) was digested with Sad and Xhol, after which the light chain PCR fragment (digested with the same restriction enzymes) was cloned into the vector, resulting in pUR4122.3. This plasmid was digested with Pstl, after which the above described about 230 bp Pstl fragment was cloned into the plasmid vector, resulting in a plasmid called pUR4143. Two orientations are possible, but selection can be made by restriction analysis, as usual. Instead of the scFv-LYS gene originally present in pUR4122, this new plasmid pUR4143 contains a gene encoding an scFv-TRAS fragment of anti-traseolide antibody 02/01/01 (for the nucleotide sequence of the 714 bp Pstl-Xhol fragment see SEQ ID NO: 12). Construction of pUR4178 and pUR4179. After digesting pUR4143 with Eagl and with HmdIII, an about 715 bp fragment can be isolated. Subsequentely, this fragment can be cloned into the vector backbone fragments of pUR2741 and pUR4175, that were digested with the same restriction enzymes. In the case of pUR2741, this resulted in plasmid pUR2743.4 (see Figure 5). This plasmid can subsequently be cleaved with Xhol and HmdIII and ligated with the about 8 kbp Xhol-Hindlll fragment of pUR4174, resulting in pUR4178 (see Figure 6). In the situation where pUR4175 was used as a starting vector, the resulting plasmid was designated pUR4179 (see Figure 7). Both plasmids, pUR4178 and pUR4179 were introduced into S. cerevisiae. Example 3. The modification of the binding parts of the chimeric protein that can bind traseolide® in order to improve the binding or release of traseolide® under certain conditions. Modification of binding properties of antibodies during the immune response is a well known immunological phenomenon originating from the fine tuning of complementarity determining sequences in the antibody's binding region to the antigen's molecular properties. This phenomenon can be mimicked in vitro by adjusting the antigen binding regions of antibody fragments based on molecular models of these regions in contact with the antigen. One such example consists of protein engineering the antimusk antibody M02/01/01 to a stronger binding variant M020501i. First, a molecular model of M02/01/01 variable fragment (Fv) was constructed by homology modelling, using the coordinates of the anti-lysozyme antibody HYHELr 10 as a template (Brookhaven Protein Data Bank entry: 3HFM). This model was refined using Molecular Mechanics and Molecular Dynamics methods from within the Biosym program DISCOVER, on a Silicon Graphics 4D240 workstation. Secondly, the binding site of the resulting Fv was mapped by visually docking the musk antigen into the CDR region, followed by a refinement using molecular dynamics again. Upon inspection of the resulting model for packing efficiency (van der Waals contact areas), it was concluded that substitution of ALA H96 by VAL would increase the (hydrophobic) contact area between the ligand and Fv, and consequently lead to a stronger interaction (see Figure 8). When this mutation is introduced into M02/01/01, the cDNA-derived scFv from Example 2, the result will be Fv M020501i; a variant with an increased affinity of at least a factor of 5 can be expected, and the increased affinity could be measured using fluorescence titration of the Fv with the musk odour molecule. Example 4. Construction of a gene encoding a chimeric protein that will be anchored in the cell wall of lower eukaryote and is able to bind hormones such as HCG. Gene fragments, encoding the variable regions of the heavy and light chain fragments from the monoclonal antibody directed against the human chorionic gonadotropin were obtained from a hybridoma cell line in a similar way as described in Example 2. Subsequently, these HCG V,, and V, gene fragments were cloned into plasmid pUR4143 by replacing the corresponding Pstl-BstEll and Sαcl- Xhol gene fragments, resulting in plasmid pUR4146. Similar to the method described in Example 2, the 734 bp Eagl-Xhol fragment (nucleotide sequence given in SEQ ID NO: 13) encoding the variable regions of the heavy and light chain fragments from the monoclonal antibody directed against the human chorionic gonadotropin (an scFv-HCG fragment) was isolated from pUR4146 and was introduced into the vector backbone fragment of pUR4178 (see Example 2) and will be introduced into the vector backbone fragment of pUR4175 (see Example 1), both digested with the same restriction enzymes. The resulting plasmids pUR4177 (see Figure 9) was, and pUR4180 (see Figure 10) will be, introduced into S. cerevisiae strain SU10. Example 5. Construction of a gene encoding a chimeric scFv-FLOl protein that will be anchored in the cell wall of lower eukaryote and is able to bind hormones such as HCG. One of the genes associated with the flocculation phenotype in S. cerevisiae is the FLOl gene. The DNA sequence of a clone containing major parts of the FLOl gene has been determined, see SEQ ID NO: 14 giving 2685 bp of the FLOl gene. The cloned fragment appeared to be approximately 2 kb shorter than the genomic copy as judged from Southern and Northern hybridizations, but encloses both ends of the FLOl gene. Analysis of the DNA sequence data indicates that the putative protein contains at the N-terminus a hydrophobic region which confirms a signal sequence for secretion, a hydrophobic C-terminus that might function as a signal for the attachment of a GPI-anchor and many glycosylation sites, especially in the C-terminus, with 46.6% serine and threonine in the arbitrarily defined C-terminus (aa 271-894). Hence, it is likely that the FLOl gene product is located in an orientated fashion in the yeast cell wall and may be directly involved in the process of interaction with neighbouring cells. The cloned FLOl sequence might therefore be suitable for the immobilization of proteins or peptides on the cell surface by a different type of cell wall anchor. For the production of a chimeric protein comprising the scFv-HCG followed by the C-terminal part of the FLOl-protein, plasmid pUR2990 (see Figure 11) can be used as a starting vector. The preparation of episomal plasmid pUR2990 was described in our co-pending patent application WO-94/01567 (UNILEVER) published on 20 January 1994, i.e. during the priority year. Plasmid pUR2990 comprises the chimeric gene consisting of the gene encoding the Humicola lipase and a gene encoding the putative C-terminal cell wall anchor domain of the FLOl gene product, the chimeric gene being preceded by the invertase signal sequence (SUC2) and the GAL7 promoter; further the plasmid comprises the yeast 2 μm sequence, the defective Leu2 promoter described by Eckard and Hollenberg (1983), and the Leu2 gene, see Roy cs. (1991). Plasmid pUR4146, described in Example 4, can be digested with Pstl and Xhol, and the about 0.7 kbp Pstl-Xhol fragment containing the scFv-HCG coding sequence can be isolated. For the in frame fusion of this DNA sequence between the C-terminal FLOl part and the SUC2 signal sequence, the fragment can be directly ligated with the 9,3 kbp Eagl/Nhel (partial) backbone of plasmid pUR2990, resulting in plasmid pUR4196 (see Figure 12). This plasmid will comprise an additional triplet encoding Ala at the transition between the SUC2 signal sequence and the start of the scFv-HCG, and a E-I-K-G-G amino acid sequence in front of the first amino acid (Ser) of the C part of FLOl protein. If in the previous Examples 1-5 the level of exposed antibody fragments is too low, the production level can be increased by mutagenesis of the frame work regions of the antibody fragment. This can be done in a site directed way or by (targeted) random mutagenesis. using techniques described in the literature. Example 6. Construction of a gene encoding a chimeric protein that will be anchored in the cell wall of a lower eukaryote and is able to bind cholesterol. In the literature two DNA secμiences for cholesterol oxidase are described, the c/ioB gene from Brevibacterium stemlicum, see Ohta c.s. (1991) and the choA gene from Streptomyces sp. SA-COO, see Ishizaka c.s. (1989). For the construction of a DNA fusion between the c//oB gene coding for cholesterol oxidase (EC 1.1.3.6) and the 3' part of the AG-αl gene, the PCR technique on chromosomal DNA can be applied. Chromosomal DNA can be isolated by standard techniques from Brevibacterium stemlicum, and the DNA part coding for the mature part of the cholesterol oxidase can be amplified through application with the following corresponding PCR primers choOlpcr and cho02pcr: choOlpcr 5 ' - Gcc ccc AGC CGc Ace CTC G-3 * = SEQ ID NO: 16 3*- CGG GGG TCG GCG TGG GAG C-5' = SEQ ID NO: 17 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 5'-AGATCTGAATTCGCGGCC GCC CCC AGC CGC ACC CTC G-3' = SEQ ID NO: 18 EcoRl Notl Eagl cho02pcr NΛel HindiII 3'-TAG TAG AGC AGG CTG TAG GTC CGATCGACTTTCGAATCTAGA-5' = SEQ ID NO: 19 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 5 ' -ATC ATC TCG TCC GAC ATC CAG- 3 * = SEQ ID NO: 20 3 ' -TAG TAG AGC AGG CTG TAG GTC- 5 ' = SEQ ID NO: 21 Both primers can specifically hybridize with the target sequence, thereby amplifying the coding part of the gene in such a way, that the specific PCR product -after Proteinase K treatment and digestion with EcoRl and HmdIII- can be directly cloned into a suitable vector, here preferably pTZ19R, see Mead cs. (1986). This will result in plasmid pUR2985 (see Figure 13). In addition to the already mentioned restriction sites both PCR primers generate other restriction sites at the 5' end and the 3' end of the 1.5 kbp DNA fragment, which can be used later on to fuse the fragment in frame between either the SUC2 signal sequence or the prepro-α-mating factor signal sequence on one side and the C-terminus coding part of the α-agglutinin gene on the other side. To facilitate the ligation behind the prepro-MF sequence a Not site is introduced at the 5' end of PCR oligonucleotide choOlpcr, allowing for example, the exchange of the 731 bp Eag/Nhel fragment containing the scFv-Lys coding sequence in pUR4175 for the c/zoB coding sequence. To create an enzymatically inactive fusion protein between cholesterol oxidase and α-agglυtinin, the above described subcloning into pTZ19R can be used. Cholesterol oxidase is an FAD-dcpcndent enzyme for which the crystal structure of the Brevibacterum stemlicum enzyme has been determined, see Vrielink cs. (1991). The enzyme displays homology with the typical pattern of the FAD-binding domain with the Gly-X-Gly-X-X-Gly sequence near the N-terminus (amino acid 18-23). Site- directed in vitro mutagenesis on the plasmid pUR2985 according to the manufacturer's protocol (Muta-Gene kit, Bio-Rad) can be applied to inactivate the FAD-binding site through replacing the triplet(s) encoding the Gly residue(s) by triplets encoding other amino acids, thereby presumably inactivating the enzyme. E.g. the following primer can be used for site-directed mutagenesis of 2 of the conserved Gly residues. pr 3'- CGG GAG CAG TAG CGG TCA CGT ATG CCG CCA CGG CAG CGG CGC -5' I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I CS 5'- GCC CTC GTC ATC GGC AGT GGA TAC GGC GGT GCC GTC GCC GCG -3' Ala Gly Gly Gly Gly Ala Ala Ala i I Ala Ale pr = primer = SEQ ID NO: 22 cs = coding strand = SEQ ID NO: 23 As a result of the mutagenesis with the described primer, plasmid pUR2986 will be obtained. From this plasmid the DNA coding for the presumably inactivated cholesterol oxidase can be released as a 1527 bp fragment through Notl/Nhel digestion, and subsequently directly used to exchange the scFv-Lys coding sequence in pUR4175, thereby generating plasmid pUR2987 (see Figure 14). To obtain a variant yeast secretion vector, where the secretion is directed through the SUC2 signal sequence, for example the 1823 bp long Sacl/Nhel segment of plasmid pUR2986 can be used to replace the Sacl/Nhel fragment in pUR4174. This inactivation of the FAD-binding site might be preferable over other mutations, since an unchanged active centre can be expected to leave the binding properties of cholesterol oxidase for cholesterol unaltered. Instead of the described Gly-Ala exchanges at position 18 and 20 of the mature coding sequence, every other suitable amino acid change can also be performed. To inactivate the enzyme, site directed mutagenesis can be optionally immediately performed in the active site cavity, for example through exchange of the Glu331, a residue appropriately positioned to act as the proton acceptor, thus generating a new variant of an immobilized, enzymatically inactive fusion protein. Example 7. Construction of a gene encoding a chimeric protein that will be anchored in the cell wall of a lactic acid bacterium and is able to bind cholesterol. It has been described that proteinase of Lactococcus lactis subsp. cremoris is anchored to the cell wall through its 127 amino acid long C-terminal, see Kok cs. (1988) and Kok (1990). In a way similar to that described in Example 6, the cholesterol oxidase of Brevibacterium ste licum (choB) can be immobilized on the surface of Lactococcus lactis. Fusions can be made can be made between the cΛoB structural gene and the N-terminal signal sequence and the C-terminal anchor of the proteinase of Lactococcus lactis. Plasmid pGKV550 (see Figure 15) contains the complete proteinase operon of Lactococcus lactis subsp. cremoris Wg2, including the promoter, a ribosome binding site and DNA fragments encoding the already mentioned signal and anchor sequences, see Kok (1990). First a DNA fragment, containing the main part of the signal sequence, flanked by a Clal site and an Eagl site can be constructed with PCR on pGKV550 as follows: Primer prtl: 5 ' -AA GAT CTA TCG ATC TTG TTA GCC GGT ACA-3 ' = SEQ ID NO: 24 Proteinase gene (non coding strand): 3 - -TT CCC GAT AGC TAG AAC AAT CGG CCA TGT CAG-5 ' Clal = SEQ ID NO: 25 Proteinase gene: Gin Ala Lys 5 ' -GTC GGC GAA ATC CAA GCA AAG GCG GCT-3 ' = SEQ ID NO: 26 Primer prt2: = SEQ ID NO: 27 3 ' -CAG CCG CTT TAG GTT CGT TGC CGG CCC CCC TTC GAA CCC-5' Eagl Hindlll After the PCR reaction as described in Example 6, the 98 bp long PCR fragment can be isolated and digested with Clal and Hindlll. pGKV550 can subsequently be cleaved partially with Clal and completely with Hindlll, after which digestions the vector fragment, containing the promoter, the ribosome binding site, the DNA fragment encoding the N-terminal 8 amino acids and the cell wall binding fragment containing the 127 C-terminal amino acids of the proteinase gene can be isolated on gel. A copy of the cholesterol oxidase gene, suitable for fusion with the prtP anchor domain can be produced by a PCR reaction using plasmid pUR2985 (Example 6) as template and a combination of primer choOlpcr (see Example 6) and the following primer cho03pcr instead of primer cho02pcr: cho03pcr HmdIII 3'-TAG TAG AGC AGG CTG TAG GTC CGA GTT CGA ACC TAG GC-5' = SEQ ID NO: 40 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 5'-ATC ATC CG TCC GAC ATC CAG = SEQ ID NO: 20. The about 1.53 kbp fragment generated by this reaction can be digested with Notl and HmdIII to produce a molecule which can subsequently be ligated with the large Eagl/Hindϊll fragment from pUR2988 (see Figure 16). The resulting plasmid, pUR2989, will contain the cholesterol oxidase coding sequence inserted between the signal sequence and the C-terminal cell wall anchor domain of the proteinase gene. After introduction into Lactobacillus lactis subsp. lactis MG1363 by electroporation, this plasmid will express cholesterol oxidase under control of the proteinase promoter. The transport through the membrane will be mediated by the proteinase signal sequence and the immobilization of the cholesterol oxidase by the proteinase anchor. As it is unlikely that the Lactococcus will secrete FAD as well, the cholesterol oxidase will not be active but will be capable to bind cholesterol. Example 8. Construction of a gene encoding a chimeric protein that will be anchored in the cell wall of a lower eukaryote and is able to bind growth hormones, such as the epidermal growth factor. For the isolation of larger amounts of human epidermal growth factor (EGF) the corresponding receptor can be used in form of a fusion between the binding domain and a C-terminal part of α-agglutinin as cell wall anchor. The complete cDNA sequence of the human epidermal growth factor is cloned and sequenced. For the construction of a fusion protein with EGF binding capacity the N-terminal part of the mature receptor until the central 23 amino acids transmenbrane region can be 5 utilized. The plasmid pUR4175 can be used for the construction. Through digestion with Eagl and Nhel (partial) a 7 1 bp DNA fragment containing the sequence coding for scFv is released and can be replaced by a DNA fragment coding for the first 621 amino acids of human epidermal growth factor receptor. Initiating from an existing 10 human cDNA library or otherwise through production of a cDNA library by standard techniques from preferentially EGF receptor overexpressing cells, e.g. A431 carcinoma cells, see Ullrich cs. (1984), further PCR can be applied for the generation of in frame linkage between the extracellular binding domain of the human growth factor receptor (amino acid 1-622) and the C-terminal part of 15 α-agglutinin. PCR oligonucleotides for the in frame linkage of human epidermal growth factor receptor and the C-terminus of α-agglutinin. 20 a: PCR oligonucleotides for the transition between SUC2 signal sequence and the N-terminus of mature EGF receptor. > mature EGF receptor pri EGF1: Ala Leu Glu Lys Lys Val = SEQ ID NO: 28 5 - -GGG GCG GCC GCG CTG GAG GAA AAG AAA GTT TGC-3 • * <■— ' ZVU l- X | | ! i i i i i j i I I | | | I I I | | ( 3 ' -CGC TCA GCC CGA GAC CTC CTT TTC TTT CAA ACG 5 • EGF rec (non-coding strand): = SEQ ID NO: 29 b: PCR oligonucleotides for the in frame transition between C terminus of the 30 extracellular binding domain of EGF receptor and the C terminal part of α-agglutinin. EGF rec (coding strand): Asn Gly Pro lie Pro Ser Ala Thr 5--AAT GGG CCT AAG ATC CCG TCC ATC GCC ACT-3 ' = SEQ ID NO: 30 I I I I I I I I i I i I i I i I i I iI i I iI I I i i i K ιtJQκj.. jOIx 3'-TTA CCC GGA TTC TAG GGC AGG CGA TCGGAATTCGAA CCCC-5 ' pr EGF2: Nhel Hindlll This fusion would result in an addition of 2 Ala amino acids between the signal sequence and the mature N-terminus of EGF receptor. The newly obtained 1.9 kbp PCR fragment can be digested with Nσtl and Nhel and directly ligated into the vector pUR4175 after digesting with the same enzymes, resulting in plasmid pUR2993 (see Figure 17), comprising the GAL7 promoter, the prepro-α-mating factor sequence, the chimeric EGF receptor binding domain gene / α-agglutinin gene, the yeast 2 μm sequence, the defective LEU2 promoter and the LEU2 gene. This plasmid can be transformed into S. cerevisiae and the transformed cells can be cultivated in YP medium whereby expression of the chimeric protein can be induced by adding galactose to the medium. Example 9. Construction of genes encoding a chimeric protein anchored to the cell wall of yeast, comprising a binding domain of a "Camelidae" heavy chain antibody Recently it was described that camels as well as a number of related species (e.g. lamas) contain a considerable amount of IgG antibody molecules which are only composed of heavy-chain dimers, see Hamers-Casterman cs. (1993). Although these "heavy-chain" antibodies are devoid of light chains, it was demonstrated, that they nevertheless have an extensive antigen-binding repertoire. In order to show that the variable regions of this type of antibodies can be produced and will be linked to the exterior of the cell wall of a yeast, the following constructs were prepared. Construction of pUR2997. pUR2998 and pUR2999 The about 2.1 kbp Eagl-Hinάl l fragment of pUR4177 (Example 4, Fig 9) was isolated. By using PCR technology, an EcoRl restriction site was introduced immediately upstream of the Eagl site, whereby the C of the EcoRl site is the same as the first C of the Eagl site. The thus obtained .EcoRl-H dIII fragment was ligated into plasmid pEMBL9, which was digested with EcoRl and HmdIII, which resulted in pUR4177.A The EcoRl/Nhel fragment of plasmid pUR4177.A was replaced by the EcoRl/Nhel fragments of three different synthetic DNA fragments (SEQ ID NO: 32, SEQ ID NO: 33, and SEQ ID NO: 34) resulting in pUR2997, pUR2998 and pUR2999, respectively. The about 1.5 kbp B.vtEII-Hmdlll fragments of pUR2997 and pUR2998 were isolated. Construction of pUR4421 The multiple cloning site of plasmid pEMBL9, see Dente c.s. (1983), (ranging from the EcoRl to the HmdIII site) was replaced by a synthetic DNA fragment having the nucleotide sequence given below, see SΕQ ID NO: 35 giving the coding strand and SΕQ ID NO: 36 giving the non-coding strand. The 5'-part of this nucleotide sequence comprises an Eagl site, the first 4 codons of a Camelidae V Η gene fragment (nucleotides 16-27) and a Xhol site (CTCGAG) coinciding with codons 5 and 6 (nucleotides 28-33). The 3'-part comprises the last 5 codons of the Camelidae V H gene (nucleotides 46-60) (part of which coincides with a -BstEII site), eleven codons of the Myc tail (nucleotides 61-93), see SEQ ID NO: 35 containing these eleven codons and SEQ ID NO: 37 giving the amino acid sequence, and an -EcoRl site (GAATTC). The EcøRI site, originally present in pEMBL9, is not functional any more, because the 5'- end of the nucleotide sequence contains AATTT instead of AATTC, indicated below as (£α?RI). The resulting plasmid is called pUR4421. The Camelidae V H fragment starts with amino acids Q-V-K and ends with amino acids V-S-S. (EcoRl) Eagl Xhol BstEII 5 '-AATTTAGCGG CCGCCCAGGT GAAACTGCTC GAGTAAGTGA CTAAGGTCAC- 50 3 ' 1 ATCGCC GGCGGGTCCA CTTTGACGAG CTCATTCACT GATTCCAGTG- 5 Q V K -CGTCTCCTCA GAACAAAAAC TCATCTCAGA AGAGGATCTG AATTAATGAG- 100 -GCAGAGGAGT CTTGTTTTTG AGTAGAGTCT TCTCCTAGAC TTAATTACTC- V S S E Q K L I S E E D L N * * = SEQ ID NO: 37 EcoRl Hindlll -AATTCATCAA ACGGTGATA -3' 119 = SEQ ID NO: 35 -TTAAGTAGTT TGCCACTATT CGA -5' 123 = SEQ ID NO: 36 Construction of pUR4424 After digesting the plasmid pB09 with Xhol and BstEII, a DNA fragment of about 0.34 kbp was isolated from agarose gel. This fragment codes for a truncated V H fragment, missing both the first 4 and the last 5 amino acids of the Camelidae V H fragment. Plasmid pB09 was deposited as E. coli JM109 pB09 at the Centraal Bureau voor Schimmelcultures, Baarn on 20 April 1993 with deposition number CBS 271.93. The DNA and amino acid sequences of the Camel V H fragments followed by the Flag sequence as present in plasmid pB09 were given in Figure 6B of European patent application 93201239.6 (not yet published), which is herein incorporated by reference. The obtained about 0.34 kbp fragment was cloned into pUR4421. To this end plasmid pUR4421 was digested with Xhol and HmdIII, after which the about 4 kb vector fragment was isolated from an agarose gel. The resulting vector was ligated with the about 0.34 kbp Xhol/BstEϊl fragment and a synthetic DNA linker having the following sequence: BstEII tfindlll GTCACCGTCTCCTCATAATGA = SEQ ID NO: 38 GCAGAGGAGTATTACTTCGA = SEQ ID NO: 39 resulting in plasmid pUR4421-09. Plasmid pSY16 was digested with Eagl and HmdIII, after which the about 6.5 kbp long vector backbone was isolated and ligated with the about 0.38 kbp Eagl/Hind l fragment from pUR4421-09 resulting in pUR4424. Construction of pUR4482 and pUR4483 From pUR4424 the about 0.44 kbp SacI--B.rtEII fragment, coding for the invertase signal sequence and the camel heavy chain variable 09 ( = CΗ V 09) fragment, was isolated as well as the about 6.3 kbp SαcI-HmdIII vector fragment. The about 6.3 kbp fragment and the about 0.44 kbp fragment from pUR4424 were ligated with the £5tEII-HmdIII fragment from pUR2997 or pUR2998 yielding pUR4482 and pUR4483, respectively. Plasmid pUR4482 is thus an yeast episomal expression plasmid for expression of a fusion protein with the invertase signal sequence, the CΗ V 09 variable region, the Myc-tail and the Camel "X-P-X-P" Hinge region, see Hamers-Casterman cs. (1993), (1993), and the α-agglutinin cell wall anchor region. Plasmid pUR4483 differs from pUR4482 in that it contains the Myc-tail but not the "X-P-X-P" Hinge region. Similarly, the β.tfEII-HmdIII fragment from pUR2999 can be ligated with the about 6.3 kbp vector fragment and the about 0.44 kbp fragment from pUR4424, resulting in pUR4497, which will differ from pUR4482 in that it contains the "X-P-X-P" Hinge region but not the Myc-tail. The plasmids pUR4424, pUR4482 and pUR4483 were introduced into Saccharomyces cerevisiae SU10 by electroporation, and transformants were selected on plates lacking leucine. Transformants from SU10 with pUR4424, pUR4482 or pUR4483, respectively, were grown on YP with 5% galactose and analysed with immuno-fluorescence microscopy, as described in Example 1 of our co-pending WO-94/01567 (UNILEVER) published on 20 January 1994. This method was slightly modified to detect the chimeric proteins, containing both the camel antibody and the Myc tail, present at the cell surface. In one method a monoclonal mouse anti-Myc antibody was used as a first antibody to bind to the Myc part of the chimeric protein; subsequently a polyclonal anti- mouse Ig antiserum labeled with fluorescein isothiocyanate (-= F--TC) ex Sigma, Product No. F-0527, was used to detect the bound mouse antibody and a positive signal was determined by fluorescence microscopy. In the other method a polyclonal rabbit anti-human IgG serum, which had earlier been proven to cross-react with the camel antibodies, was used as a first antibody to bind the camel antibody part of the chimeric protein; subsequently a polyclonal anti- rabbit Ig antiserum labeled with FITC ex Sigma, Product No. F-0382, was used to detect the bound rabbit antibody and a positive signal was determined by fluorescence microscopy. The results in Figure 19 and Figure 20 show clearly that fluorescence can be obser¬ ved on those cells in which a fusion protein of the CH V 09 fragment with the α- agglutinin cell wall anchor region is produced (pUR4482 and pUR4483). No fluorescence however, was visible on the cells which produce the CH V 09 fragment without this anchor (pUR4424), when viewed under the same circumstances. Patent literature references: EP-Al-0255153 (UNILEVER) Production of guar alpha-galactosidase by hosts transformed by recombinant DNA methods. First priority date 03.06.86; published 03.02.88 WO-91/00920 (UNILEVER) Process for preparing a protein by a fungus transformed by multicopy integration of an expression vector. First priority date 07.07.89; published 24.01.91 WO-91/19782 (UNILEVER) Xylanase production. Priority date 19.06.90; published 26.12.91 WO-94/01567 (UNILEVER) Process for immobilizing enzymes to the cell wall of a microbial cell by producing a fusion protein. First priority date 08.07.92; published 20.01.94 EP patent application 93201239.6 (not yet published) Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of Camelidae. Filing date 29.04.93 Non-patent literature references: R.E. Bird & B. Webb Walker Single chain antibody variable regions. TIBTECH 2 (April 1991) 132-137 A. Conzelmann, C. Fankhauser & C. Desponds Myoinositol gets incorporated into numerous membrane glycoproteins of Saccharomyces cerevisiae; incorporation is dependent on phosphomannomutase (SEC53). The EMBO Journal 9, No.3 (1990) 653-661 L. Dente, G. Cesareni & R. Cortese pEMBL: a new family of single stranded plasmids. Nucleic Acids Research U, No. 6 (1983) 1645-1655 E. Erhart, & C.P. Hollenberg The Presence of a Defective Leu2 Gene on 2μ DNA Recombinant Plasmids of Saccharomyces cerevisiae Is Responsible for Curing and High Copy Number. Journal of Bacteriology. 156, No.2 (Nov. 1983) 625-635 C. Hamers-Casterman, T. Atarhouch, S.Muyldermans, G. Robinson, C. Hamers, E. Bajyana Songa, N. Bcndahman & R. Hamers Naturally occurring antibodies devoid of light chains. Nature 363 (3 June 1993) 446-448. M.M. Harmsen, A.C. Langedijk, E. van Tuinen, R.H. Geerse, H.A. Raue, & J. Maat Effect of pmrl disruption and different signal sequences on the intracellular processing and secretion of Cyamopsis tetragonoloba α-galactosidase by Saccharomyces cerevisiae. Gene 125 ( 1993) 1 15-123 T. Ishizaki, N. Hirayama, H. Shinkawa, O. Nimi, & Y. Murooka Nucleotide Sequence of the Gene for Cholesterol Oxidase from a Streptomyces sp. Journal of Bacteriology 171, No.l (Jan. 1989) 596-601 J. Kok, K.J. Leenhouls, A.J. Haandrikman, A.M. Ledeboer & G. Venema Nucleotide Sequence of the Cell Wall Proteinase Gene of Streptococcus cremoris Wg2. Applied and Environmental Microbiology 54, No. 1 (Jan. 1988) 231-238 J. Kok Genetics of the proteolytic system of lactic acid bacteria. FEMS Microbiology Reviews. 87 (1990) 15-42, esp. item 3.2 and Figure 7 on pages 22-23 R. Lewin The universal constructor set. New Scientist (8 December 1990) 30-33 P.N. Lipke, D. Wojciechowicz & J. Kurjan AGal Is the Structural Gene for the Saccharomyces cerevisiae α-Aggl tinin, a Cell Surface Glycoprotein Involved in Cell- Cell Interactions during Mating. Molecular and Cellular Biology. 2 . No.8 (Aug. 1989) 3155-3165. DA. Mead, E. Szczesna-Skorupa & B. Ke per Single-stranded DNA 'blue' T7 promoter plasmids: a versatile tandem promoter system for cloning and protein engineering. Protein Engineering I, No. 1 (1986) 67-74 R. Orlandi, D.H. Gϋssow, P.T. Jones, & G. Winter Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86 (May 1989) 3833-3837 B.C. Ossendorp The non-specific lip id -transfer binding protein: a recombinant DNA and immunological approach. Thesis University of Utrecht (30 September 1992) T. Ohta, K. Fujishiro, K. Yamaguchi, Y. Tamura, K. Aisaka, T. Uwajima & M. Hasegawa Sequence of gene choB encoding cholesterol oxidase oi Brevibacterium stemlicum: comparison with choA oi Streptomyces sp. SA-COO. Gene 103 (1991) 93-96 A. Roy, C.F. Lu, D.L. Marykwas, P.N. Lipke & J. Kurjan The AGA1 Product Is Involved in Cell Surface Attachment of the Saccharomyces cerevisiae Cell Adhesion Glycoprotein a-Agglutinin. Molecular and Cellular Biology H No.8 (Aug. 1991) 4196-4206 M.P. Schreuder, S. Brekelmans, H. van den Ende, & F.M. Klis Targeting of a Heterologous Protein to the Cell Wall of Saccharomyces cerevisiae. Yeast 9 (1993) 399-409 A. Ullrich, L. Coussens, J.S. Hayflick, TJ. Dull, A Gray, A.W. Tarn, J. Lee, Y. Yarden, TA. Libermann, J. Schlessinger, J. Downward, E.L.V. Mayes, N. Whittle, M.D. Waterfield & P.H. Seeburg Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 30_£ (31 May 1984) 418*425 J.MA. Verbakel Heterologous gene expression in the yeast Saccharomyces cerevisiae. Thesis University of Utrecht (1 May 1991), esp. pages 76-89 A Vrielink, L.F. Lloyd, & D.M. Blow Crystal Structure of Cholesterol Oxidase from Brevibacterium stemlicum Refined at 1.8 A Resolution. J. Mol. Biol., 212 (1991) 533-554 E.S. Ward, D. Gϋssow, AD. Griffiths, P.T. Jones & G. Winter. Binding activities of a repertoire of single immunoglobulin variable domains secreted from E. coli. Nature 341 (12 October 1989) 544-546 Information on a deposit of a micro-organism under the Budapest Treaty is given on page 26, lines 5-7 above . In agreement with Rule 28 (4) EPC, or a similar arrangement for a State not being a Contracting State of the EPC, it is hereby requested that a sample of such deposit, when requested, will be submitted to an expert only. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A NAME: Unilever N.V. (B STREET: Weena 455 (C CITY: Rotterdam (E COUNTRY: The Netherlands (F POSTAL CODE (ZIP): NL-3013 AL (A NAME: Unilever PLC (B STREET: Unilever House Blackfriars (C CITY: London (E COUNTRY: United Kingdom (F POSTAL CODE (ZIP): EC4P 4BQ (A NAME: Leon Gerardus J. FRENKEN (B STREET: Geldersestraat 90 (C CITY: Rotterdam (E COUNTRY: The Netherlands (F POSTAL CODE (ZIP): NL-3011 MP (A NAME: Pieter DE GEUS (B STREET: Boeier 24 (C CITY: Barendrecht (E COUNTRY: The Netherlands (F POSTAL CODE (ZIP): NL-2991 KB (A NAME: Franciscus Maria KLIS (B STREET: Benedenlangs 102 (C CITY: Amsterdam (E COUNTRY: The Netherlands (F POSTAL CODE (ZIP): NL-1025 KL (A NAME: Holger York TOSCHKA; c/o Langneεe Iglo, BR3 (B STREET: Aeckern 1 (C CITY: REKEN (E COUNTRY: Germany (F POSTAL CODE (ZIP): D-48734 (A NAME: Cornelis Theodorus VERRIPS (B STREET: Hagedoorn 18 (C CITY: 2-iaassluis (E COUNTRY: The Netherlands (F POSTAL CODE (ZIP): NL-3142 KB (ii) TITLE OF INVENTION: Immobilized proteins with specific binding capacities and their use in processes and products. (iii) NUMBER OF SEQUENCES: 40 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (EPO) (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 231 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: fragment in pUR4119 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: GAATTCGAGC TCATCACACA AACAAACAAA ACAAAATGAT GCTTTTGCAA GCCTTTCTTT 60 TCCTTTTGGC TGGTTTTGCA GCCAAAATAT CTGCGCAGGT GCAGCTGCAG TAATGAACCA 120 CGGTCACCGT CTCCTCAGGT GGAGGCGGTT CAGGCGGAGG TGGCTCTGGC GGTGGCGGAT 180 CGGACATCGA GCTCACTCAG ACCAAGCTCG AGATCAAACG GTGATAAGCT T 231 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: linker Xhol-Nhel coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: TCGAGATCAA AGGCGGATCT G 21 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: linker Xhol-Nhel non-coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: CTAGCAGATC CGCCTTTGAT C 21 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: linker Eagl-Pstl coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: GGCCGCCCAG GTGCAGCTGC A 21 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (Vii) IMMEDIATE SOURCE: (B) CLONE: linker Eagl-Pstl non-coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: GCTGCACCTG GGC 13 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: PCR primer A (heavy chain) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: AGGTSMARCT GCAGSAGTCW GG 22 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: PCR primer B (heavy chain) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: TGAGGAGACG GTGACCGTGG TCCCTTGGCC CC 32 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: PCR primer C (light chain) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: GACATTGAGC TCACCCAGTC TCCA 24 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: PCR primer D (light chain) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: GTTTGATCTC GAGCTTGGTC CC 22 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: linker EcoRI-Pstl coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: AATTCGGCCG TTCAGGTGCA GCTGCA 26 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: linker EcoRI-Pstl non-coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: GCTGCACCTG AACGGCCG 18 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 714 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: ScFv antitraseolide 02/01/01 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: CTGCAGGAGT CTGGACCTGG CCTGGTGAAA CCTTCTCAGT CTCTGTCCCT CACCTGCACT 60 GTCACTGGCT ACTCAATCAC CAGTGATTTT GCCTGGAACT GGATCCGGCA GTTTCCAGGA 120 AACCAACTGG AGTGGATGGG CTACATAAGC TACAGTGGTA GCACTAGCTA CAACCCATCT 180 CTCAAAAGTC GAATCTCTCT CACTCGAGAC ACATCCAAGA ACCAGTTCTT CCTGCAGTTG 240 AATTCTGTGA CTACTGAGGA CACAGCCACA TATTACTGTG CAACGTCCCT AACATGGTTA 300 CTACGTCGGA AACGTTCTTA CTGGGGCCAA GGGACCACGG TCACCGTCTC CTCAGGTGGA 360 GGCGGTTCAG GCGGAGGTGG CTCTGGCGGT GGCGGATCGG ACATCGAGCT CACCCAGTCT 420 CCATCCTCCA TGTCTGTATC TCTGGGAGAC ACAGTCAGCA TCACTTGCCA TGCAAGTCAG 480 GACATTAGCA GTAATATAGG GTGGTTGCAG CAGAAACCAG GGAAATCATT TAAGGGCCTG 540 ATCTATCATG GAACCAACTT GGAAGATGGT ATTCCATCAA GGTTCAGTGG CAGTGGATCT 600 GGAGCAGATT ATTCCCTCAC CATCAGCAGC CTGGAATCTG AAGATTTTGC AGACTATTAC 660 TGTGTACAGT ATGCTCAGTT TCCATTCACG TTCGGCTCGG GGACCAAGCT CGAG 714 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 734 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: ScFv anti-HCG (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: CGGCCGTTCA GGTGCAGCTG CAGGAGTCTG GGGGACACTT AGTGAAGCCT GGAGGGTCCC 60 TGAAACTCTC CTGTGCAGCC TCTGGATTCG CTTTCAGTAG CTTTGACATG TCTTGGATTC 120 GCCAGACTCC GGAGAAGAGG CTGGAGTGGG TCGCAAGCAT TACTAATGTT GGTACTTACA 180 CCTACTATCC AGGCAGTGTG AAGGGCCGAT TCTCCATCTC CAGAGACAAT GCCAGGAACA 240 CCCTAAACCT GCAAATGAGC AGTCTGAGGT CTGAGGACAC GGCCTTGTAT TTCTGTGCAA 300 GACAGGGGAC TGCGGCACAA CCTTACTGGT ACTTCGATGT CTGGGGCCAA GGGACCACGG 360 TCACCGTCTC CTCAGGTGGA GGCGGTTCAG GCGGAGGTGG CTCTGGCGGT GGCGGATCGG 420 ACATCGAGCT CACCCAGTCT CCAAAATCCA TGTCCATGTC CGTAGGAGAG AGGGTCACCT 480 TGAGCTGCAA GGCCAGTGAG ACTGTGGATT CTTTTGTGTC CTGGTATCAA CAGAAACCAG 540 AACAGTCTCC TAAATTGTTG ATATTCGGGG CATCCAACCG GTTCAGTGGG GTCCCCGATC 600 GCTTCACTGG CAGTGGATCT GCAACAGACT TCACTCTGAC CATCAGCAGT GTGCAGGCTG 660 AGGACTTTGC GGATTACCAC TGTGGACAGA CTTACAATCA TCCGTATACG TTCGGAGGGG 720 GGACCAAGCT CGAG 734 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2685 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Saccharomyces cerevisiae (vii) IMMEDIATE SOURCE: (B) CLONE: pYY105 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2685 (D) OTHER INFORMATION: /product= "Flocculation protein" /gene= "FLOl" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: ATG ACA ATG CCT CAT CGC TAT ATG TTT TTG GCA GTC TTT ACA CTT CTG 48 Met Thr Met Pro His Arg Tyr Met Phe Leu Ala Val Phe Thr Leu Leu 1 5 10 15 GCA CTA ACT AGT GTG GCC TCA GGA GCC ACA GAG GCG TGC TTA CCA GCA 96 Ala Leu Thr Ser Val Ala Ser Gly Ala Thr Glu Ala Cys Leu Pro Ala 20 25 30 GGC CAG AGG AAA AGT GGG ATG AAT ATA AAT TTT TAC CAG TAT TCA TTG 144 Gly Gin Arg Lys Ser Gly Met Asn lie Asn Phe Tyr Gin Tyr Ser Leu 35 40 45 AAA GAT TCC TCC ACA TAT TCG AAT GCA GCA TAT ATG GCT TAT GGA TAT 192 Lys Asp Ser Ser Thr Tyr Ser Asn Ala Ala Tyr Met Ala Tyr Gly Tyr 50 55 60 GCC TCA AAA ACC AAA CTA GGT TCT GTC GGA GGA CAA ACT GAT ATC TCG 240 Ala Ser Lys Thr Lys Leu Gly Ser Val Gly Gly Gin Thr Asp lie Ser 65 70 75 80 ATT GAT TAT AAT ATT CCC TGT GTT AGT TCA TCA GGC ACA TTT CCT TGT 288 lie Asp Tyr Asn lie Pro Cys Val Ser Ser Ser Gly Thr Phe Pro Cys 85 90 95 CCT CAA GAA GAT TCC TAT GGA AAC TGG GGA TGC AAA GGA ATG GGT GCT 336 Pro Gin Glu Asp Ser Tyr Gly Asn Trp Gly Cys Lys Gly Met Gly Ala 100 105 110 TGT TCT AAT AGT CAA GGA ATT GCA TAC TGG AGT ACT GAT TTA TTT GGT 384 Cys Ser Asn Ser Gin Gly lie Ala Tyr Trp Ser Thr Asp Leu Phe Gly 115 120 125 TTC TAT ACT ACC CCA ACA AAC GTA ACC CTA GAA ATG ACA GGT TAT TTT 432 Phe Tyr Thr Thr Pro Thr Asn Val Thr Leu Glu Met Thr Gly Tyr Phe 130 135 140 TTA CCA CCA CAG ACG GGT TCT TAC ACA TTC AAG TTT GCT ACA GTT GAC 480 Leu Pro Pro Gin Thr Gly Ser Tyr Thr Phe Lys Phe Ala Thr Val Asp 145 150 155 160 GAC TCT GCA ATT CTA TCA GTA GGT GGT GCA ACC GCG TTC AAC TGT TGT 528 Asp Ser Ala lie Leu Ser Val Gly Gly Ala Thr Ala Phe Asn Cys Cys 165 170 175 GCT CAA CAG CAA CCG CCG ATC ACA TCA ACG AAC TTT ACC ATT GAC GGT 576 Ala Gin Gin Gin Pro Pro He Thr Ser Thr Asn Phe Thr He Asp Gly 180 185 190 ATC AAG CCA TGG GGT GGA AGT TTG CCA CCT AAT ATC GAA GGA ACC GTC 624 He Lys Pro Trp Gly Gly Ser Leu Pro Pro Asn He Glu Gly Thr Val 195 200 205 TAT ATG TAC GCT GGC TAC TAT TAT CCA ATG AAG GTT GTT TAC TCG AAC 672 Tyr Met Tyr Ala Gly Tyr Tyr Tyr Pro Met Lys Val Val Tyr Ser Asn 210 215 220 GCT GTT TCT TGG GGT ACA CTT CCA ATT AGT GTG ACA CTT CCA GAT GGT 720 Ala Val Ser Trp Gly Thr Leu Pro He Ser Val Thr Leu Pro Asp Gly 225 230 235 240 ACC ACT GTA AGT GAT GAC TTC GAA GGG TAC GTC TAT TCC TTT GAC GAT 768 Thr Thr Val Ser Asp Asp Phe Glu Gly Tyr Val Tyr Ser Phe Asp Asp 245 250 255 GAC CTA AGT CAA TCT AAC TGT ACT GTC CCT GAC CCT TCA AAT TAT GCT 816 Asp Leu Ser Gin Ser Asn Cys Thr Val Pro Asp Pro Ser Asn Tyr Ala 260 265 270 GTC AGT ACC ACT ACA ACT ACA ACG GAA CCA TGG ACC GGT ACT TTC ACT 864 Val Ser Thr Thr Thr Thr Thr Thr Glu Pro Trp Thr Gly Thr Phe Thr 275 280 285 TCT ACA TCT ACT GAA ATG ACC ACC GTC ACC GGT ACC AAC GGC GTT CCA 912 Ser Thr Ser Thr Glu Met Thr Thr Val Thr Gly Thr Asn Gly Val Pro 290 295 300 ACT GAC GAA ACC GTC ATT GTC ATC AGA ACT CCA ACC AGT GAA GGT CTA 960 Thr Asp Glu Thr Val He Val He Arg Thr Pro Thr Ser Glu Gly Leu 305 310 315 320 ATC AGC ACC ACC ACT GAA CCA TGG ACT GGC ACT TTC ACT TCG ACT TCC 1008 He Ser Thr Thr Thr Glu Pro Trp Thr Gly Thr Phe Thr Ser Thr Ser 325 330 335 ACT GAG GTT ACC ACC ATC ACT GGA ACC AAC GGT CAA CCA ACT GAC GAA 1056 Thr Glu Val Thr Thr He Thr Gly Thr Asn Gly Gin Pro Thr Asp Glu 340 345 350 ACT GTG ATT GTT ATC AGA ACT CCA ACC AGT GAA GGT CTA ATC AGC ACC 1104 Thr Val He Val He Arg Thr Pro Thr Ser Glu Gly Leu He Ser Thr 355 360 365 ACC ACT GAA CCA TGG ACT GGT ACT TTC ACT TCT ACA TCT ACT GAA ATG 1152 Thr Thr Glu Pro Trp Thr Gly Thr Phe Thr Ser Thr Ser Thr Glu Met 370 375 380 ACC ACC GTC ACC GGT ACT AAC GGT CAA CCA ACT GAC GAA ACC GTG ATT 1200 Thr Thr Val Thr Gly Thr Asn Gly Gin Pro Thr Asp Glu Thr Val He 385 390 395 400 GTT ATC AGA ACT CCA ACC AGT GAA GGT TTG GTT ACA ACC ACC ACT GAA 1248 Val He Arg Thr Pro Thr Ser Glu Gly Leu Val Thr Thr Thr Thr Glu 405 410 415 CCA TGG ACT GGT ACT TTT ACT TCG ACT TCC ACT GAA ATG TCT ACT GTC 1296 Pro Trp Thr Gly Thr Phe Thr Ser Thr Ser Thr Glu Met Ser Thr Val 420 425 430 ACT GGA ACC AAT GGC TTG CCA ACT GAT GAA ACT GTC ATT GTT GTC AAA 1344 Thr Gly Thr Asn Gly Leu Pro Thr Asp Glu Thr Val He Val Val Lys 435 440 445 ACT CCA ACT ACT GCC ATC TCA TCC AGT TTG TCA TCA TCA TCT TCA GGA 1392 Thr Pro Thr Thr Ala He Ser Ser Ser Leu Ser Ser Ser Ser Ser Gly 450 455 460 CAA ATC ACC AGC TCT ATC ACG TCT TCG CGT CCA ATT ATT ACC CCA TTC 1440 Gin He Thr Ser Ser He Thr Ser Ser Arg Pro He He Thr Pro Phe 465 470 475 480 TAT CCT AGC AAT GGA ACT TCT GTG ATT TCT TCC TCA GTA ATT TCT TCC 1488 Tyr Pro Ser Asn Gly Thr Ser Val He Ser Ser Ser Val He Ser Ser 485 490 495 TCA GTC ACT TCT TCT CTA TTC ACT TCT TCT CCA GTC ATT TCT TCC TCA 1536 Ser Val Thr Ser Ser Leu Phe Thr Ser Ser Pro Val He Ser Ser Ser 500 505 510 GTC ATT TCT TCT TCT ACA ACA ACC TCC ACT TCT ATA TTT TCT GAA TCA 1584 Val He Ser Ser Ser Thr Thr Thr Ser Thr Ser He Phe Ser Glu Ser 515 520 525 TCT AAA TCA TCC GTC ATT CCA ACC AGT AGT TCC ACC TCT GGT TCT TCT 1632 Ser Lys Ser Ser Val He Pro Thr Ser Ser Ser Thr Ser Gly Ser Ser 530 535 540 GAG AGC GAA ACG AGT TCA GCT GGT TCT GTC TCT TCT TCC TCT TTT ATC 1680 Glu Ser Glu Thr Ser Ser Ala Gly Ser Val Ser Ser Ser Ser Phe He 545 550 555 560 TCT TCT GAA TCA TCA AAA TCT CCT ACA TAT TCT TCT TCA TCA TTA CCA 1728 Ser Ser Glu Ser Ser Lys Ser Pro Thr Tyr Ser Ser Ser Ser Leu Pro 565 570 575 CTT GTT ACC AGT GCG ACA ACA AGC CAG GAA ACT GCT TCT TCA TTA CCA 1776 Leu Val Thr Ser Ala Thr Thr Ser Gin Glu Thr Ala Ser Ser Leu Pro 580 585 590 CCT GCT ACC ACT ACA AAA ACG AGC GAA CAA ACC ACT TTG GTT ACC GTG 1824 Pro Ala Thr Thr Thr Lys Thr Ser Glu Gin Thr Thr Leu Val Thr Val 595 600 605 ACA TCC TGC GAG TCT CAT GTG TGC ACT GAA TCC ATC TCC CCT GCG ATT 1872 Thr Ser Cys Glu Ser His Val Cys Thr Glu Ser He Ser Pro Ala He 610 615 620 GTT TCC ACA GCT ACT GTT ACT GTT AGC GGC GTC ACA ACA GAG TAT ACC 1920 Val Ser Thr Ala Thr Val Thr Val Ser Gly Val Thr Thr Glu Tyr Thr 625 630 635 640 ACA TGG TGC CCT ATT TCT ACT ACA GAG ACA ACA AAG CAA ACC AAA GGG 1968 Thr Trp Cys Pro He Ser Thr Thr Glu Thr Thr Lys Gin Thr Lys Gly 645 650 655 ACA ACA GAG CAA ACC ACA GAA ACA ACA AAA CAA ACC ACG GTA GTT ACA 2016 Thr Thr Glu Gin Thr Thr Glu Thr Thr Lys Gin Thr Thr Val Val Thr 660 665 670 ATT TCT TCT TGT GAA TCT GAC GTA TGC TCT AAG ACT GCT TCT CCA GCC 2064 He Ser Ser Cys Glu Ser Asp Val Cys Ser Lys Thr Ala Ser Pro Ala 675 680 685 ATT GTA TCT ACA AGC ACT GCT ACT ATT AAC GGC GTT ACT ACA GAA TAC 2112 He Val Ser Thr Ser Thr Ala Thr He Asn Gly Val Thr Thr Glu Tyr 690 695 700 ACA ACA TGG TGT CCT ATT TCC ACC ACA GAA TCG AGG CAA CAA ACA ACG 2160 Thr Thr Trp Cys Pro He Ser Thr Thr Glu Ser Arg Gin Gin Thr Thr 705 710 715 720 CTA GTT ACT GTT ACT TCC TGC GAA TCT GGT GTG TGT TCC GAA ACT GCT 2208 Leu Val Thr Val Thr Ser Cys Glu Ser Gly Val Cys Ser Glu Thr Ala 725 730 735 TCA CCT GCC ATT GTT TCG ACG GCC ACG GCT ACT GTG AAT GAT GTT GTT 2256 Ser Pro Ala He Val Ser Thr Ala Thr Ala Thr Val Asn Asp Val Val 740 745 750 ACG GTC TAT CCT ACA TGG AGG CCA CAG ACT GCG AAT GAA GAG TCT GTC 2304 Thr Val Tyr Pro Thr Trp Arg Pro Gin Thr Ala Asn Glu Glu Ser Val 755 760 765 AGC TCT AAA ATG AAC AGT GCT ACC GGT GAG ACA ACA ACC AAT ACT TTA 2352 Ser Ser Lys Met Asn Ser Ala Thr Gly Glu Thr Thr Thr Asn Thr Leu 770 775 780 GCT GCT GAA ACG ACT ACC AAT ACT GTA GCT GCT GAG ACG ATT ACC AAT 2400 Ala Ala Glu Thr Thr Thr Asn Thr Val Ala Ala Glu Thr He Thr Asn 785 790 795 800 ACT GGA GCT GCT GAG ACG AAA ACA GTA GTC ACC TCT TCG CTT TCA AGA 2448 Thr Gly Ala Ala Glu Thr Lys Thr Val Val Thr Ser Ser Leu Ser Arg 805 810 815 TCT AAT CAC GCT GAA ACA CAG ACG GCT TCC GCG ACC GAT GTG ATT GGT 2496 Ser Asn His Ala Glu Thr Gin Thr Ala Ser Ala Thr Asp Val He Gly 820 825 830 CAC AGC AGT AGT GTT GTT TCT GTA TCC GAA ACT GGC AAC ACC AAG AGT 2544 His Ser Ser Ser Val Val Ser Val Ser Glu Thr Gly Asn Thr Lys Ser 835 840 845 CTA ACA AGT TCC GGG TTG AGT ACT ATG TCG CAA CAG CCT CGT AGC ACA 2592 Leu Thr Ser Ser Gly Leu Ser Thr Met Ser Gin Gin Pro Arg Ser Thr 850 855 860 CCA GCA AGC AGC ATG GTA GGA TAT AGT ACA GCT TCT TTA GAA ATT TCA 2640 Pro Ala Ser Ser Met Val Gly Tyr Ser Thr Ala Ser Leu Glu He Ser 865 870 875 880 ACG TAT GCT GGC AGT GCA ACA GCT TAC TGG CCG GTA GTG GTT TAA 2685 Thr Tyr Ala Gly Ser Ala Thr Ala Tyr Trp Pro Val Val Val 885 890 895 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 894 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: Met Thr Met Pro His Arg Tyr Met Phe Leu Ala Val Phe Thr Leu Leu 1 5 10 15 Ala Leu Thr Ser Val Ala Ser Gly Ala Thr Glu Ala Cys Leu Pro Ala 20 25 30 Gly Gin Arg Lys Ser Gly Met Asn He Asn Phe Tyr Gin Tyr Ser Leu 35 40 45 Lys Asp Ser Ser Thr Tyr Ser Asn Ala Ala Tyr Met Ala Tyr Gly Tyr 50 55 60 Ala Ser Lys Thr Lys Leu Gly Ser Val Gly Gly Gin Thr Asp He Ser 65 70 75 80 He Asp Tyr Asn He Pro Cys Val Ser Ser Ser Gly Thr Phe Pro Cys 85 90 95 Pro Gin Glu Asp Ser Tyr Gly Asn Trp Gly Cys Lys Gly Met Gly Ala 100 105 110 Cys Ser Asn Ser Gin Gly He Ala Tyr Trp Ser Thr Asp Leu Phe Gly 115 120 125 Phe Tyr Thr Thr Pro Thr Asn Val Thr Leu Glu Met Thr Gly Tyr Phe 130 135 140 Leu Pro Pro Gin Thr Gly Ser Tyr Thr Phe Lys Phe Ala Thr Val Asp 145 150 155 160 Asp Ser Ala He Leu Ser Val Gly Gly Ala Thr Ala Phe Asn Cys Cys 165 170 175 Ala Gin Gin Gin Pro Pro He Thr Ser Thr Asn Phe Thr He Asp Gly 180 185 190 He Lys Pro Trp Gly Gly Ser Leu Pro Pro Asn He Glu Gly Thr Val 195 200 205 Tyr Met Tyr Ala Gly Tyr Tyr Tyr Pro Met Lys Val Val Tyr Ser Asn 210 215 220 Ala Val Ser Trp Gly Thr Leu Pro He Ser Val Thr Leu Pro Asp Gly 225 230 235 240 Thr Thr Val Ser Asp Asp Phe Glu Gly Tyr Val Tyr Ser Phe Asp Asp 245 250 255 Asp Leu Ser Gin Ser Asn Cys Thr Val Pro Asp Pro Ser Asn Tyr Ala 260 265 270 Val Ser Thr Thr Thr Thr Thr Thr Glu Pro Trp Thr Gly Thr Phe Thr 275 280 285 Ser Thr Ser Thr Glu Met Thr Thr Val Thr Gly Thr Asn Gly Val Pro 290 295 300 Thr Asp Glu Thr Val He Val He Arg Thr Pro Thr Ser Glu Gly Leu 305 310 315 320 He Ser Thr Thr Thr Glu Pro Trp Thr Gly Thr Phe Thr Ser Thr Ser 325 330 335 Thr Glu Val Thr Thr He Thr Gly Thr Asn Gly Gin Pro Thr Asp Glu 340 345 350 Thr Val He Val He Arg Thr Pro Thr Ser Glu Gly Leu He Ser Thr 355 360 365 Thr Thr Glu Pro Trp Thr Gly Thr Phe Thr Ser Thr Ser Thr Glu Met 370 375 380 Thr Thr Val Thr Gly Thr Asn Gly Gin Pro Thr Asp Glu Thr Val He 385 390 395 400 Val He Arg Thr Pro Thr Ser Glu Gly Leu Val Thr Thr Thr Thr Glu 405 410 415 Pro Trp Thr Gly Thr Phe Thr Ser Thr Ser Thr Glu Met Ser Thr Val 420 425 430 Thr Gly Thr Asn Gly Leu Pro Thr Asp Glu Thr Val He Val Val Lys 435 440 445 Thr Pro Thr Thr Ala He Ser Ser Ser Leu Ser Ser Ser Ser Ser Gly 450 455 460 Gin He Thr Ser Ser He Thr Ser Ser Arg Pro He He Thr Pro Phe 465 470 475 480 Tyr Pro Ser Asn Gly Thr Ser Val He Ser Ser Ser Val He Ser Ser 485 490 495 Ser Val Thr Ser Ser Leu Phe Thr Ser Ser Pro Val He Ser Ser Ser 500 505 510 Val He Ser Ser Ser Thr Thr Thr Ser Thr Ser He Phe Ser Glu Ser 515 520 525 Ser Lys Ser Ser Val He Pro Thr Ser Ser Ser Thr Ser Gly Ser Ser 530 535 540 Glu Ser Glu Thr Ser Ser Ala Gly Ser Val Ser Ser Ser Ser Phe He 545 550 555 560 Ser Ser Glu Ser Ser Lys Ser Pro Thr Tyr Ser Ser Ser Ser Leu Pro 565 570 575 Leu Val Thr Ser Ala Thr Thr Ser Gin Glu Thr Ala Ser Ser Leu Pro 580 585 590 Pro Ala Thr Thr Thr Lys Thr Ser Glu Gin Thr Thr Leu Val Thr Val 595 600 605 Thr Ser Cys Glu Ser His Val Cys Thr Glu Ser He Ser Pro Ala He 610 615 620 Val Ser Thr Ala Thr Val Thr Val Ser Gly Val Thr Thr Glu Tyr Thr 625 630 635 640 Thr Trp Cys Pro He Ser Thr Thr Glu Thr Thr Lys Gin Thr Lys Gly 645 650 655 Thr Thr Glu Gin Thr Thr Glu Thr Thr Lys Gin Thr Thr Val Val Thr 660 665 670 He Ser Ser Cys Glu Ser Asp Val Cys Ser Lys Thr Ala Ser Pro Ala 675 680 685 He Val Ser Thr Ser Thr Ala Thr He Asn Gly Val Thr Thr Glu Tyr 690 695 700 Thr Thr Trp Cys Pro He Ser Thr Thr Glu Ser Arg Gin Gin Thr Thr 705 710 715 720 Leu Val Thr Val Thr Ser Cys Glu Ser Gly Val Cys Ser Glu Thr Ala 725 730 735 Ser Pro Ala He Val Ser Thr Ala Thr Ala Thr Val Asn Asp Val Val 740 745 750 Thr Val Tyr Pro Thr Trp Arg Pro Gin Thr Ala Asn Glu Glu Ser Val 755 760 765 Ser Ser Lys Met Asn Ser Ala Thr Gly Glu Thr Thr Thr Asn Thr Leu 770 775 780 Ala Ala Glu Thr Thr Thr Asn Thr Val Ala Ala Glu Thr He Thr Asn 785 790 795 800 Thr Gly Ala Ala Glu Thr Lys Thr Val Val Thr Ser Ser Leu Ser Arg 805 810 815 Ser Asn His Ala Glu Thr Gin Thr Ala Ser Ala Thr Asp Val He Gly 820 825 830 His Ser Ser Ser Val Val Ser Val Ser Glu Thr Gly Asn Thr Lys Ser 835 840 845 Leu Thr Ser Ser Gly Leu Ser Thr Met Ser Gin Gin Pro Arg Ser Thr 850 855 860 Pro Ala Ser Ser Met Val Gly Tyr Ser Thr Ala Ser Leu Glu He Ser 865 870 875 880 Thr Tyr Ala Gly Ser Ala Thr Ala Tyr Trp Pro Val Val Val 885 890 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: ChoB template coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: GCCCCCAGCC GCACCCTCG 19 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: ChoB template non-coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: CGAGGGTGCG GCTGGGGGC 19 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: choOlpcr primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: AGATCTGAAT TCGCGGCCGC CCCCAGCCGC ACCCTCG 37 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: cho02pcr primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: AGATCTAAGC TTTCAGCTAG CCTGGATGTC GGACGAGATG AT 42 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: ChoB template coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: ATCATCTCGT CCGACATCCA G 21 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: ChoB template non-coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: CTGGATGTCG GACGAGATGA T 21 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: mutagenesis primer ChoB (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: CGCGGCGACG GCACCGCCGT ATGCACTGGC GATGACGAGG GC 42 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: ChoB template coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: GCCCTCGTCA TCGGCAGTGG ATACGGCGGT GCCGTCGCCG CG 42 (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: primer prtl (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: AAGATCTATC GATCTTGTTA GCCGGTACA 29 (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: proteinase template non-coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: GACTGTACCG GCTAACAAGA TCGATAGCCC TT 32 (2) INFORMATION FOR SEQ ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: proteinase template coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: GTCGGCGAAA TCCAAGCAAA GGCGGCT 27 (2) INFORMATION FOR SEQ ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: prt2 primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: CCCAAGCTTC CCCCCGGCCG TTGCTTGGAT TTCGCCGAC 39 (2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: EGF1 primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: GGGGCGGCCG CGCTGGAGGA AAAGAAAGTT TGC 33 (2) INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: EGF receptor template non-coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29: GCAAACTTTC TTTTCCTCCA GAGCCCGACT CGC 33 (2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: EGF receptor template coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: AATGGGCCTA AGATCCCGTC CATCGCCACT 30 (2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 40 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: EGF2 primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: CCCCAAGCTT AAGGCTAGCG GACGGGATCT TAGGCCCATT 40 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 177 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: VhC - AGαl linker with MycT and Hinge (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: GAATTCCAGG TCACCGTCTC CTCAGAACAA AAACTCATCT CAGAAGAGGA TCTGAATGAA 60 CCAAAGATTC CACAACCTCA ACCAAAGCCA CAACCTCAAC CACAACCACA ACCAAAACCT 120 CAACCAAAGC CAGAACCAGA ATCTACTTCC CCAAAGTCTC CAGCTAGCCT TAAGCTT 177 (2) INFORMATION FOR SEQ ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 63 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: VhC - AGαl linker with MycT (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33: GAATTCCAGG TCACCGTCTC CTCAGAACAA AAACTCATCT CAGAAGAGGA TCTGAATGCT 60 AGC 63 (2) INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 144 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: VhC - AGαl linker with Hinge (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: GAATTCCAGG TCACCGTCTC CTCAGAACCA AAGATTCCAC AACCTCAACC AAAGCCACAA 60 CCTCAACCAC AACCACAACC AAAACCTCAA CCAAAGCCAG AACCAGAATC TACTTCCCCA 120 AAGTCTCCAG CTAGCCTTAA GCTT 144 (2) INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 119 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: fragment in pUR4421 coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: AATTTAGCGG CCGCCCAGGT GAAACTGCTC GAGTAAGTGA CTAAGGTCAC CGTCTCCTCA 60 GAACAAAAAC TCATCTCAGA AGAGGATCTG AATTAATGAG AATTCATCAA ACGGTGATA 119 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 119 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: fragment in pUR4421 non-coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: AGCTTATCAC CGTTTGATGA ATTCTCATTA ATTCAGATCC TCTTCTGAGA TGAGTTTTTG 60 TTCTGAGGAG ACGGTGACCT TAGTCACTTA CTCGAGCAGT TTCACCTGGG CGGCCGCTA 119 (2) INFORMATION FOR SEQ ID NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (vii) IMMEDIATE SOURCE: (B) CLONE: Myc tail (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37: Glu Gin Lys Leu lie Ser Glu Glu Asp Leu Asn 1 5 10 (2) INFORMATION FOR SEQ ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: BstEII-Hindlll linker coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38: GTCACCGTCT CCTCATAATG A 21 (2) INFORMATION FOR SEQ ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: BstEII Hindlll linker non-coding strand (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39: AGCTTCATTA TGAGGAGACG 20 (2) INFORMATION FOR SEQ ID NO: 40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vii) IMMEDIATE SOURCE: (B) CLONE: primer cho03pcr (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40: CGGATCCAAG CTTGAGCCTG GATGTCGGAC GAGATGAT 38

Claims: C L A I M S 1. A method for immobilizing a binding protein capable of binding to a spe¬ cific compound, comprising the use of recombinant DNA techniques for producing said binding protein or a functional part thereof still having said specific binding capability, said protein or said part thereof being linked to the outside of a host cell, whereby said binding protein or said part thereof is localized in the cell wall or at the exterior of the cell wall by allowing the host cell to produce and secrete a chimeric protein in which said binding protein or said functional part thereof is bound with its C-terminus to the N-terminus of an anchoring part of an anchoring protein capable of anchoring in the cell wall of the host cell, which anchoring part is derivable from the C-terminal part of said anchoring protein. 2. The method of claim 1, in which the host is selected from the group consisting of Gram-positive bacteria and fungi. 3. The method of claim 2, in which the host is a Gram-positive bacterium selected from the group consisting of lactic acid bacteria, and bacteria belonging to the genera Bacillus and Streptomyces. 4. The method of claim 2, in which the host is a fungus selected from the group consisting of yeasts belonging to the genera Candida, Debaryomyces, Han- senula, Kluyveromyces, Pichia and Saccharomyces, and moulds belonging to the genera Aspergillus, Penicillium and Rhizopus. 5. A recombinant polynucleotide comprising (i) a structural gene encoding a binding protein or a functional part thereof still having the specific binding capability, and (ii) at least part of a gene encoding an anchoring protein capable of anchoring in the cell wall of a Gram-positive bacterium or a fungus, said part of a gene encoding at least the anchoring part of said anchoring protein, which anchoring part is derivable from the C-terminal part of said anchoring protein. 6. The polynucleotide of claim 5, wherein the anchoring protein is selected from the group consisting of α-agglutinin, a-agglutinin, FLOl, the Major Cell Wall Protein of a fungus, and proteinase of lactic acid bacteria. 7. The polynucleotide of claim 5, further comprising a nucleotide sequence encoding a signal peptide ensuring secretion of the expression product of the polynucleotide. 8. The polynucleotide of claim 7, wherein the signal peptide is derived from a protein selected from the group consisting of the α-mating factor of yeast, α-agglu¬ tinin of yeast, invertase oi Saccharomyces, inulinase oi Kluyveromyces, α-amylase of Bacillus, and proteinase of lactic acid bacteria. 9. The polynucleotide of any of claims 5-8, operably linked to a promoter, which can be an inducible promoter. 10. A recombinant vector comprising a polynucleotide as claimed in any of claims 5-9. 11. A chimeric protein encoded by a polynucleotide as claimed in any of claims 5-9. 12. A host cell having a cell wall at the outside of its cell and containing at least one polynucleotide as claimed in any of claims 5-9. 13. The host cell of claim 12, having at least one polynucleotide as claimed in any of claims 5-9 integrated in its chromosome. 14. A host cell having a chimeric protein as claimed in claim 11 immobilized in its cell wall and having the binding protein part of the chimeric protein localized in the cell wall or at the exterior of the cell wall. 15. The host cell of any of claims 12-14, which is a fungus selected from the group consisting of yeasts and moulds. 16. A process for carrying out an isolation process by using an immobilized binding protein or functional part thereof still capable of binding to a specific compound, wherein a medium containing said specific compound is contacted with a host cell as claimed in any of claims 12-15 under conditions whereby a complex between said specific compound and said immobilized binding protein is formed, separating said complex from the medium originally containing said specific compound and, optionally, releasing said specific compound from said binding protein or functional part thereof. » « « * *

Inventors: DE GEUS PIETER, FRENKEN LEON GERARDUS J, KLIS FRANCISCUS MARIA, TOSCHKA HOLGER YORK, VERRIPS CORNELIS THEODORUS, DE GEUS, PIETER, FRENKEN, LEON, GERARDUS, J., KLIS, FRANCISCUS, MARIA, TOSCHKA, HOLGER, YORK, VERRIPS, CORNELIS, THEODORUS
Applicants: FRENKEN LEON GERARDUS J, GEUS PIETER DE, KLIS FRANCISCUS MARIA, TOSCHKA HOLGER YORK, UNILEVER NV, UNILEVER PLC, VERRIPS CORNELIS THEODORUS, DE GEUS, PIETER, FRENKEN, LEON, GERARDUS, J., KLIS, FRANCISCUS, MARIA, TOSCHKA, HOLGER, YORK, UNILEVER N.V., VERRIPS, CORNELIS, THEODORUS
Application year: 1994
Main classification: C12N15
IPC codes: C07H21, C07K14, C07K16, C07K19, C12N1, C12N11, C12N15, C12P21, C12R1